STRIDE (tremelimumab + durvalumab)
Checked 2026-09-09
Unresectable hepatocellular carcinoma, first line
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Tremelimumab Monoclonal antibody (anti-CTLA-4) | 300 mg single priming dose | IV | D1 | cycle 1 only |
Durvalumab Monoclonal antibody (anti-PD-L1) | 1,500 mg | IV | D1 |
Cycles
until progression
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.